Sativex Multiple-Sclerosis Spray
UK drugmaker GW Pharmaceuticals and Japan's Otsuka Pharmaceutical have entered into a long-term alliance which will focus on the development of cannabinoid-based drugs. The firms said that the accord was initiated when GW granted Otsuka an exclusive license to develop and market Sativex, the UK company's oro-mucosal anti-pain spray, in the USA.
Under the terms of the deal, which is subject to Hart-Scott-Rodino clearance in the USA, GW will receive an $18.0 million upfront fee when the deal is signed and could earn up to $273.0 million in milestone payments. In addition, the UK firm will establish a long-term commercial supply contract…
Under the terms of the deal, which is subject to Hart-Scott-Rodino clearance in the USA, GW will receive an $18.0 million upfront fee when the deal is signed and could earn up to $273.0 million in milestone payments. In addition, the UK firm will establish a long-term commercial supply contract…